Abstract: The present invention is directed to siRNA molecules which specifically target and cause RNAi-induced degradation of mRNA from TPTE genes, so that the protein product of the TPTE gene is not produced or is produced in reduced amounts. The siRNA compounds and compositions of the invention are useful for treating diseases which require inhibition of TPTE expression for their treatment, in particular cancer pathologies. The present invention also includes methods which make possible to assess and/or prognose the metastatic behaviour of a cancer disease and/or the occurrence of a relapse of cancer.
Type:
Application
Filed:
December 7, 2006
Publication date:
September 3, 2009
Applicant:
GANYMED PHARMACEUTICALS AG
Inventors:
Ugur Sahin, Özlem Türeci, Michael Koslowski
Abstract: The invention relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the invention also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors, and to the nucleic acids coding for the polypeptides, peptides and proteins.
Type:
Grant
Filed:
November 21, 2003
Date of Patent:
May 5, 2009
Assignee:
Ganymed Pharmaceuticals AG
Inventors:
Ugur Sahin, Ozlem Türeci, Michael Koslowski
Abstract: The invention relates to the identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which said genetic products that are expressed in association with a tumor are expressed in an aberrant manner. The invention also relates to proteins, polypeptides, and peptides which are expressed in association with a tumor and the nucleic acids coding therefor.
Type:
Grant
Filed:
March 12, 2003
Date of Patent:
September 30, 2008
Assignee:
Ganymed Pharmaceuticals AG
Inventors:
Ugur Sahin, Ozlem Tureci, Michael Koslowski
Abstract: According to the invention, tumour-associated gene products and nucleic acids coding therefor were identified. The present invention relates to the therapy and diagnosis of diseases wherein said tumour-associated gene products are expressed aberrantly. The invention also relates to proteins, polypeptides and peptides which are expressed in a tumour-associated manner and the nucleic acids coding therefor.
Type:
Application
Filed:
September 23, 2004
Publication date:
July 10, 2008
Applicant:
GANYMED PHARMACEUTICALS AG
Inventors:
Ozlem Tureci, Ugur Sahin, Gerd Helftenbein, Volker Schluter
Abstract: According to the invention, gene products expressed in a tumor-associated manner and the nucleic acids coding therefor were identified. The invention relates to the therapy and diagnosis of diseases wherein said gene products expressed in a tumor-associated manner are aberrantly expressed. The invention also relates to proteins, polypeptides and peptides which are expressed in a tumor associated manner and to nucleic acids coding therefor.
Type:
Application
Filed:
May 18, 2005
Publication date:
July 10, 2008
Applicant:
Ganymed Pharmaceuticals AG
Inventors:
Ozlem Tureci, Ugur Sahin, Michael Koslowski
Abstract: A peptide comprising the amino acid sequence RMFPNAPYL (SEQ ID NO:1) or a portion or variant thereof provided that the peptide is not intact human WT-1 polypeptide or a peptide comprising the amino acid sequence CMTWNQMNL (SEQ ID NO:2) or a portion or variant thereof provided that the peptide is not intact human WT-1 polypeptide or a peptide comprising the amino acid sequence HLMPFPGPLL (SEQ ID NO:3) or a portion or variant thereof provided that the peptide is not intact human gata-1 polypeptide, and polynucleotides encoding these peptides. The peptides and polynucleotides are useful as cancer vaccines.